
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc is strategically enhancing its clinical updates and expanding its program pipeline, which includes promising products like VK2809, VK5211, and VK0214, contributing to an optimistic sentiment ahead of critical clinical readouts. The company's differentiation through VK2735 and an upcoming amylin agonist IND positions it favorably for lucrative partnerships and financing opportunities, supporting its advanced standing among independent late-stage metabolic players. Furthermore, Viking's maturity and robust data relative to peers allow it to leverage renewed investor interest, enhancing its potential for growth in a rapidly evolving market.
Bears say
Viking Therapeutics Inc. is subject to significant risks inherent in the biopharmaceutical industry, including the potential for unexpected outcomes from clinical trials and regulatory uncertainties that could impede progress. Additionally, the complexity of the commercial markets for its product candidates may further exacerbate the challenges it faces, particularly as pricing pressures increase. The heightened scrutiny of licensing deals, especially those involving US and China entities, adds an additional layer of concern regarding the company's ability to navigate its growth prospects effectively.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares